Johnson & Johnson said that its mid-stage study of icotrokinra, for the treatment of moderate to severe active ulcerative ...

Johnson & Johnson announced positive topline results from ANTHEM-UC, a Phase 2b study of icotrokinra, the first investigational targeted ...

Johnson & Johnson announced that Health Canada has issued a Notice of Compliance for Lazcluze in combination with Rybrevant for the ...

Discover the strengths & weaknesses of healthcare giants Johnson & Johnson and Pfizer. Find out which stock is more promising ...